Evidence map›Paper›PMID 36346244›Full record

ArticlemBio2022

Origin and Dynamics of Mycobacterium tuberculosis Subpopulations That Predictably Generate Drug Tolerance and Resistance.

Jees Sebastian, Anooja Thomas, Carly Levine, Riju Shrestha, Shawn Levy, Hassan Safi, Sri Ram Pentakota, Pradeep Kumar, David Alland

Open access · goldAbstract read
In one paragraph

Article in mBio, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Single-cell recordings reveal subpopulations that grow and generate resistance at bactericidal concentrations of antibiotics.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Jees SebastianDepartment of Medicine, Division of Infectious Disease, Ruy V. Lourenco Center for the Study of Emerging and Re-emerging Pathogens, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Anooja ThomasDepartment of Hydrology, Indian Institute of Technology, Roorkee, Uttarakhand, India.
Carly LevineDepartment of Medicine, Division of Infectious Disease, Ruy V. Lourenco Center for the Study of Emerging and Re-emerging Pathogens, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Riju ShresthaDepartment of Medicine, Division of Infectious Disease, Ruy V. Lourenco Center for the Study of Emerging and Re-emerging Pathogens, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Shawn LevyGenomics Services Laboratory, HudsonAlpha Institute for Biotechnology, Huntsville, Alabama, USA.
Hassan SafiDepartment of Medicine, Division of Infectious Disease, Ruy V. Lourenco Center for the Study of Emerging and Re-emerging Pathogens, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Sri Ram PentakotaDepartment of Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Pradeep KumarDepartment of Medicine, Division of Infectious Disease, Ruy V. Lourenco Center for the Study of Emerging and Re-emerging Pathogens, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
David AllandDepartment of Medicine, Division of Infectious Disease, Ruy V. Lourenco Center for the Study of Emerging and Re-emerging Pathogens, Rutgers New Jersey Medical School, Newark, New Jersey, USA.ORCID 0000-0001-5196-1571
Rutgers, The State University of New Jersey · USHudsonAlpha Institute for Biotechnology · USIndian Institute of Technology Roorkee · IN

Funding

Systems Biology CoreU19AI162598 · NIAID · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI RUSSELL, DAVID G · 2021 to 2025
$13.9M
NIAID NIH HHS U19 AI162598
6 · The paper itself

Abstract

Initial responses to tuberculosis treatment are poor predictors of final therapeutic outcomes in drug-susceptible disease, suggesting that treatment success depends on features that are hidden within a small minority of the overall infecting Mycobacterium tuberculosis population. We developed a multitranswell robotic system to perform numerous parallel cultures of genetically barcoded M. tuberculosis exposed to steady-state concentrations of rifampicin to uncover these difficult-to-eliminate minority populations. We found that tolerance emerged repeatedly from at least two subpopulations of barcoded cells, namely, one that could not grow on solid agar media and a second that could form colonies, but whose kill curves diverged from the general bacterial population within 4 and 16 days of drug exposure, respectively. These tolerant subpopulations reproducibly passed through a phase characterized by multiple unfixed resistance mutations followed by emergent drug resistance in some cultures. Barcodes associated with drug resistance identified an especially privileged subpopulation that was rarely eliminated despite 20 days of drug treatment even in cultures that did not contain any drug-resistant mutants. The association of this evolutionary scenario with a defined subset of barcodes across multiple independent cultures suggested a transiently heritable phenotype, and indeed,

Indexed as

Mycobacterium tuberculosisTuberculosisAntitubercular AgentsDrug Resistance, BacterialDrug ToleranceHumansRifampinAntitubercular AgentsRifampinantibiotic resistanceantibiotic tolerancechromosomal barcodingMycobacterium tuberculosis

Identifiers

PMID36346244
PMCPMC9765434
OpenAlexW4308507941

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.